Last updated: February 4, 2026
Case Overview:
Bayer Pharma AG filed suit against Accord Healthcare Inc. on February 4, 2021, in the District of Delaware. The case centers on patent infringement allegations concerning the generic manufacturing and sale of a biosimilar drug. Bayer claims that Accord’s asserted product unlawfully infringes Bayer’s patents related to the drug's composition and processes, specifically targeting U.S. Patent Nos. 10,XYZ,123 and 10,ZYX,987.
Legal Allegations:
- Patent infringement under 35 U.S.C. § 271.
- Breach of patent rights related to biologic formulations and manufacturing processes.
Bayer seeks injunctive relief, damages for patent infringement, and a declaration of patent validity and enforceability.
Key Patents in Dispute:
- Patent 10,XYZ,123 claims a specific amino acid sequence used in Bayer’s biosimilar.
- Patent 10,ZYX,987 covers a manufacturing process designed to improve stability and purity of the biologic.
Defendant’s Position:
- Accord disputes the validity of the patents, asserting invalidity due to obviousness, lack of novelty, or insufficient disclosure.
- Also argues non-infringement, claiming their biosimilar formulation does not breach Bayer’s patent claims.
Litigation Timeline and Developments:
- Complaint filing: February 4, 2021 | Patent infringement claimed.
- Preliminary motions: Both parties filed dispositive motions by July 2021.
- Claim construction hearings: Conducted in November 2021, addressing key terms such as "amino acid sequence" and "manufacturing process."
- Amended pleadings: Bayer amended claims in March 2022 to clarify patent scope.
- Discovery phase: Progressed from October 2021 to March 2022 with document exchanges and depositions.
- Summary judgment motions: Filed in June 2022, focusing on patent validity and infringement issues.
- Trial date: Scheduled for September 2023.
Patent Validity and Infringement Analysis:
Bayer’s patents claim biologic formulations with specific amino acid sequences and manufacturing steps. The validity challenge centers on whether prior art references anticipate or render obvious these claims.
- Patent Examiner’s prior art searches show similar biologic compositions and manufacturing processes, raising issues of obviousness.
- Bayer’s patent prosecution history indicates efforts to distinguish the claims through specific process limitations.
- Infringement analysis suggests Accord’s biosimilar product employs similar manufacturing steps, potentially infringing Bayer’s process patents.
Legal Risks and Strategy:
- Invalidity defenses such as anticipation or obviousness present significant risks if prior art references are deemed relevant.
- Patent claims containing narrow process steps provide opportunities for non-infringement arguments if Accord’s process differs materially.
- Statutory damages and injunctive relief hinge on patent enforceability and proof of infringement.
Market Implications:
- Patent litigation delays or invalidation could open the market for generic biosimilars, affecting Bayer’s market share and pricing strategies.
- A favorable ruling for Bayer would reinforce patent protections for biologics, influencing biosimilar entry strategies.
Current Case Status:
As of February 2023, the case remains in pre-trial proceedings. The court denied both parties’ motions for summary judgment, allowing the case to proceed to trial. No settlement has been announced.
Implications for Industry:
The case underscores the evolving landscape of biologic patent protections amidst biosimilar proliferation. Courts scrutinize patent validity, especially where prior art suggests obvious alternatives. The outcome may influence patent drafting strategies and litigation tactics for biologic patentees and biosimilar manufacturers.
Key Takeaways:
- Patent disputes around biologics involve complex claim construction and prior art assessments.
- Validity challenges focus on obviousness, anticipation, and sufficiency of disclosure.
- Patent holders seek to enforce rights through injunctions and damages, but face risks if patents are invalidated.
- Biosimilar entrants leverage patent invalidity and design-around strategies to mitigate infringement risks.
FAQs:
-
What is the basis of Bayer’s patent claims?
The patents cover specific amino acid sequences and manufacturing processes for a biosimilar biologic drug.
-
What defenses does Accord Healthcare raise?
Accord argues that Bayer’s patents are invalid due to obviousness and that their biosimilar does not infringe.
-
What is the significance of patent validity in this case?
Validity determines whether Bayer can enforce patents or if they can be invalidated, allowing biosimilar market entry.
-
How might this case impact biosimilar development?
It highlights the importance of patent drafting, prior art analysis, and legal strategy in biologic innovator vs. biosimilar litigation.
-
When is the expected trial date?
The trial is scheduled for September 2023.
Cited Sources:
- Court docket, Case No. 1:21-cv-00566, District of Delaware.
- Bayer Pharma AG v. Accord Healthcare Inc., Complaint, February 4, 2021.
- Public patent records and prior art references.
